GILEAD SCIENCES buy signals on D1.GILEAD SCIENCES, daily timeframe: Support zone + Side of Bollinger Bands + Hammer
Gilead
ridethepig | Gilead to ATH's with Remdesivir📍 The effect of Remdesivir...
The power to unlock the all time highs via Covid is systematically, within reach rather fast, due to the nature of drug prices which are inelastic. The effect of Gilead being treated as utility is heightened by DT putting the big orders in.
Compare the following two diagrams:
Phase III trials & Chinese red carpet
Buyers maintaining a strong floor.
In the first, you will notice how once we got the break of the channel buyers were allowed to go wandering all the way to the target on grounds of safety! The second wave looks inevitable despite the political fairydust around re-openings, stimulus is running out and now the attempt to reinstate pockets of further lockdowns will make activity immovable.
Thus the question, why adding more Gilead?
When building a long/short portfolio, we must add hedges and blocks accordingly. The strategic protection with Gilead is pragmatic, 450 million new customers unlocked via European clearance & we already got the ✅ for the red carpet from China. Complacency around the virus is remarkable, UK cheerleading "Super Saturday" and US "Independence Day" ... who would have thought we are in the middle of a pandemic. In any case... An attractive constellation for a swing towards all time highs.
Thanks as usual for keeping the feedback coming 👍 or 👎
Bullish Charts - Oversold & Undervalued Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, such as cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; oncology, such as biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Sutent, Xtandi, Xalkori, Inlyta, Braftovi + Mektovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Vfend, and Zithromax brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, and tick-borne encephalitis under the Prevnar 13/Prevenar 13 (pediatric/adult), FSME-IMMUN, Nimenrix, and Trumenba brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, Genotropin, and Refacto AF/Xyntha brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company and Astellas Pharma US, Inc.; licensing agreement with Akcea Therapeutics, Inc; strategic alliance with Verily Life Sciences LLC; collaboration agreement with Merck KGaA; clinical trial collaboration and supply agreement with IDEAYA Biosciences, Inc.; material transfer and collaboration agreement with BioNTech SE to co-develop COVID-19 vaccine; clinical supply collaboration Jiangsu Alphamab Biopharmaceuticals Co., Ltd; and collaboration with Valneva SE to develop and commercialize Valneva's Lyme disease vaccine candidate VLA15. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Pfizer is one of the most unappreciated stocks in its industry and the low price shows.
Recently, institutions have taken notice and started upgrading the stock with price targets north of $40.00 a share.
Pfizer is also working on a COVID-19 vaccine and could be months ahead of other companies.
On the daily chart, the stock is sitting is sitting and bouncing off support around $33.00.
It's ready for a move up any day.
Long!
Gilead Sciences Technical AnalysisTechnical Analysis:
HOLD BEFORE GOING LONG -Wait that the resistance level will be broken before buying.
Fundamental Information:
Gilead Was Approached by AstraZeneca About Potential Merger
Can the New FDA Nod of Approval Push Gilead to New Highs
U.S. FDA approved Gilead Sciences Inc.’s experimental antiviral drug, remdesivir, for use as it’s showing good signs of helping hospitalised patients recover more quickly from Corona Virus.
From a Trend Analysis perspective - price action has been very choppy with lots of buying and selling in an almost Up-trending consolidation.
We expect Gilead to push higher with this recent news coupled with it Beating Earning Expectations for Q1 2020. This stock isnt a value stock with a PE of 18x and a Price to Book of 4x but it isn't overly expensive considering its growth potential (PEG 5yr 0.57).
GILEAD VS COVID-19NYT: FDA PERMISSION FOR GILEAD AGAINST COVID-19 IN EMERGENCIES MAY BE ANNOUNCED ALREADY TODAY
Buy now
Sell levels on the chart
Profit +250-400 %
Wish you luck !
Gilead in tested channelGILD has seen positive price action YTD; due to combatting the COVID-19 with their drug Remdesivir.
Yesterday on the news, the trial on humans which was set in China to prove the effectivity of the drug, apparently "failed". However... The price just took us to the lower part of the channel , meaning the Risk-Reward-Ratio is at a good stance.
A close below the 50sma would change the sentiment, and remove us from the channel.
GILEAD Short Term Uptrend Trade PlanTrade Plan for Gilead Sciences.
Will look to enter at bottom of uptrend channel (75.3) , Stop Loss once uptrend broken (74).
Target Price at 86. Potential Price at 96. Personally will take profit at resistances as insurance.
Upside for Gilead:
1a) Possible treatment for Covid-19 (Remdesivir)
1b) Possible 2nd wave of virus
2) Possible FDA approval of Arthritis drug
Downside for Gilead:
1) Leaked report of Remdesivir failing in China randomized trial, which was cancelled early due to low enrollment numbers. Bears clinging on hopes that the conclusion was inaccurate due to short duration of study
GileadGILD- If you didn't hear the news, yesterday Gilead labs were accredited with a drug that has been positively treating COVID19 patients. I checked the price and it is very expensive already. I had a look at the chart today and noticed that the last time this stock crossed golden (50/200 MA) on the weekly, it skyrocketed. On top of that, it held support like a champ. That moment is about to happen yet again. It is high risk due to price, you have to allocate less shares to spare your capital and an appropriate stop loss is at the weekly 200 MA. You must be ok to lose about $12 a share if the trade goes south but I see a massive opportunity in the works.
Gilead WeeklyDown to 60 / 47 up to 170 In the future.
Deepest pullback to 25 zone. Don't see it happening. This will be the first bounce off the red ribbon. Usually it is always quite strong once we touch it.
Good buy zones :
$42 - 50
Good sell zone:
$150 - 170
Buy the cureGilead says that they have a coronavirus treatment in route.
The chart looks great too.
Worst case, we have a minor leg down to the .382 line, but long term I'm bullish. (note: I am long on calls for this into the summer.)
ridethepig | GILD 2019-nCoV TargetA good time to review the previous floor at 60.xx that we have been tracking for almost a year in $GILD. Here taking the latest misses in Q4 Earnings with a pinch of salt as the red carpet has been rolled out for Gild via China. Once again another buying opportunity given the latest progress around Phase III clinical trials:
On the Remdesivir (GS-5734) side, this is their free pass into the Chinese Healthcare system. Models will need to start quickly repricing revenue from the Hep B cases in China. GILD will do the heavy lifting here, +/- $20 upside available on the headline for FDA approval which looks around the corner. Flow-wise, the initial target area from the latest technical break comes into play at 86.xx (+25% from current levels).
As usual thanks for keeping the support coming with likes, comments and etc!
Gilead Sciences Coronavirus experimental cure long opportunityBeen doing research on the progress of a coronavirus cure and severity of the outbreak. My intention was never to look for companies to invest in, I was genuinely curious about the state of the world. I came across an article (replace parenthesis with period): www() bloomberg()
com/news/articles/2020-02-01/coronavirus-case-treated-with-gilead-drug-may-spur-wider-tests
in which it is stated that the first case in the USA was treated with an experimental drug developed by gilead sciences. I encourage you to the read the article yourself and dyor. After taking a look at the chart, i couldn't help but notice that price seemed to be gearing up to go higher. Again, I encourage you to do your own analysis and not go based purely off of mine. I think this could be an amazing swing trade if played right and especially if the drug comes around to be approved.
Another article to do further research is a statement from gilead's website (replace parenthesis with period): www()gilead()
com/news-and-press/company-statements/gilead-sciences-statement-on-the-company-ongoing-response-to-the-2019-new-coronavirus
It mentions cooperation with china and an expedited plan to do clinical testing of the drug.
Best of luck and happy trading!
GILD Falling WedgesGILD seems to be forming a long term bottom, the presence of two falling wedges displays the possible repeating bullish nature of this chart. Green fractal indicates a long term target price of ~100. If downsides occur a stop loss is placed. MACD can be observed to be also rising. Volume is not always a great indicator of price movement but in a more mature market such as this, volume spikes can be interpreted as bullish signs.
Time to get defensive in $GILDThe global slowdown is coming and it is time to get defensive. Here we are reaching the end of the road to the downside in Gilead and a perfect instrument to work the flows with.
We are tracking a break of the channel to unlock the +11% move. Let's see how it plays out over the coming days.
Best of luck
Gilead Sciences offering a beautiful long setupTraders, i wanted to share this setup with you that i am trading.
I have had this stock for a while on my watchlist, and was waiting for a correction to buy the dip.
I like to buy low (cheap) in strong stocks showing upside potential.
I particularly was watching the 72$ level (200DMA, 61% fibo this is a big level. The bulls seem to have made a bottom now on this level, and finished the week with a bullish engulfing pattern, engulfing the previous 3 days.
For me this is a sign of higher prices coming in the coming days and maybe weeks.
I am targeting 80$ but keep also an eye on the 76.50$ level. If you like to wait for a small dip into 73.00$ you would get an astonishing R:R of 8:1.
Placing my stop below the the engulfing bar and will manage the trade accordingly.
Hope you like this setup :)
Thanks for reading, and blessings to you all.
October 26 Earnings: Gilead - Flying the KiteGilead's core product pipeline, including recent FDA approval is set to soar as key drugs and generics are continuing to outperform.
The company's recent acquisition of KITE Pharma came at the perfect moment with KITE being granted a key drug approval by the FDA.
Gilead's recent cost cutting efforts and R&D focus are to further push growth prospect and boost overall FY guidance.
Generic competition will continue to weigh, however, and limit some blockbuster drug expansion.
I'm starting Gilead with a $90 PT for an extended post-earnings move.
A S/L at $75 around recent area is advised.
